Huajin Sinogen Announces Appointment of Mr. Huang Wei as Vice President of the Company

Recently, Guangzhou Huajin Pharmaceutical Technology Co., Ltd. announced the appointment of Mr. Huang Wei as vice president of the company. Mr. Huang Wei directly reports to Dr. Zhao Zijian, founder and president of the company, and will focus on the company's capital operation, business development and brand strategic planning. Huajin Pharmaceutical is an original new drug research and development enterprise that is about to enter the clinical stage. It is committed to the development of innovative biological anti-tumor drugs to meet the needs of the global malignant tumor treatment market.

Huang has more than 15 years of experience in pharmaceutical marketing, business development and equity investment. Prior to joining Huajin Pharmaceuticals, Mr. Huang Wei worked for a number of multinational pharmaceutical companies and listed companies such as Novartis, GlaxoSmithKline and Luyan Pharmaceuticals, and served as senior investment director, vice president and industry partner at Wenzheng Asset. Mr. Huang Wei graduated from West China School of Pharmacy, Sichuan University, majoring in pharmacy. He holds a double degree in economics and an MBA degree from Xiamen University.

Huang WeiMBA

Vice President Business Development